Treatment and Prognoses in XXXX With Primary Gastrointestinal Stromal Tumors >= 10cm: A Single-Institution Experience in China.

@entity1 @entity2194 @entity674 @entity2213 @entity1349
UNASSIGNED: Data on treatments and specific outcomes of primary @entity674 ( @entity674 ) >= 10cm are limited. We here report the treatments and survival outcomes concerning a subgroup of primary @entity674 .Data of 83 consecutive @entity1 with primary @entity674 >= 10cm in a single institution were retrospectively collected. Fifty-eight @entity1 underwent surgery before @entity2213 mesylate (IM) treatment (Group A), 10 underwent surgical resection following IM therapy (Group B), whereas 15 @entity1 took IM as drug therapy alone (Group C).The baseline clinical characteristics were similar among the 3 groups. However, a lower proportion in Group A had metastatic disease at the time of diagnosis or surgery compared with Groups B and C (8.6% vs 40.0% vs 40.0%, P<0.05). The median follow-up duration was 21.5 months. No statistically significant differences were observed on progression-free survival (PFS) among the groups. However, @entity1 in Group B showed significantly better @entity1349 ( @entity1349 ) compared with those in Group C (P=0.044). Multivariate analysis showed that @entity1 treated with adjuvant IM were associated with better PFS (hazard ratio [HR] 3.01; 95% confidence interval [CI] 1.13-7.97; P=0.027) and @entity1349 (HR 29.11; 95% CI 3.32-125.36; P=0.004). The subgroup with mitotic count >10/50 @entity2194 ( @entity2194 ) showed worse PFS (HR 3.50; 95% CI 1.19-10.25; P=0.022) and @entity1349 (HR 20.04; 95% CI 1.67-143.79; P=0.018) than that of mitotic count  <=5/50 @entity2194 .Clinical treatment patterns for primary @entity674 are different, and the outcomes of different interventions vary. The optimal treatments for these subgroup of @entity1 still require further long-term investigation. Moreover, mitotic count and adjuvant IM are closely associated with PFS and @entity1349 in @entity674 .
